CJC-1295 Deep Dive: GHRH Analog Research Explained

CJC-1295 shows up constantly in growth-hormone-related research discussions, often paired with Ipamorelin. This profile looks at what CJC-1295 actually is, the important DAC vs. non-DAC distinction that changes how it behaves, and what's publicly known about its pharmaceutical development history.

What It Is

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) — the naturally occurring hormone that signals the pituitary gland to release growth hormone. It was engineered to resist rapid enzymatic breakdown, which is the main limitation of natural GHRH in a research or clinical setting.

The DAC vs. No-DAC Distinction

This is the single most important technical detail to understand about CJC-1295, and it's frequently glossed over:

• CJC-1295 with DAC (Drug Affinity Complex) is modified to bind to albumin in the blood, extending its activity over several days.
• CJC-1295 without DAC (sometimes sold under the name Mod GRF 1-29) has a much shorter activity window, closer to natural GHRH.

These are meaningfully different research tools with different pharmacokinetic profiles, despite often being discussed interchangeably online. Any research literature or product listing should clearly specify which version is being referenced.

Proposed Mechanism

As a GHRH analog, CJC-1295 is studied for its ability to stimulate the pituitary gland's natural, pulsatile release of growth hormone — as opposed to directly supplying growth hormone itself. This distinction (stimulating the body's own release pattern vs. direct hormone administration) is central to why GHRH analogs are studied as a separate category from synthetic HGH.

What Research Has Explored

• Growth hormone secretion patterns — the primary and best-documented research area.
• Combination research with GH secretagogues like Ipamorelin, exploring whether pairing a GHRH analog with a ghrelin-mimetic produces a more pronounced GH pulse than either alone.
• Body composition and metabolic research — a downstream area of interest given growth hormone's broader physiological role.

Evidence Quality

GHRH analogs as a drug class have a real pharmaceutical development history — GHRH-based approaches have been explored by biotech and pharmaceutical developers for growth hormone deficiency and related indications, giving the underlying mechanism a foundation in registered research. That said, publicly available data specific to CJC-1295 as sold in the research market is considerably thinner than the mechanistic rationale would suggest, and most detailed effects discussed online (particularly long-term body composition claims) are not backed by large, controlled human trials specific to this exact compound.

Safety & Research Considerations

Because CJC-1295 (particularly the DAC version) has an extended activity window, and because "CJC-1295" is used loosely online to refer to two pharmacologically distinct products, precise labeling and verified identity testing are especially important here. A Certificate of Analysis that confirms exactly which variant you're looking at is essential — see our supplier checklist.

Bottom Line

CJC-1295 is mechanistically well-grounded as a GHRH analog, but the DAC/non-DAC distinction is critical to understand, and specific human outcome data for the research-market compound remains limited compared to the broader GHRH research base.